Yes that matches my understanding. As to where the cells are actually being harvested and expanded, I have no idea.
Agreed that they are using Tigenix's adipose MSC's rather than Mesoblast's bone marrow sourced MSC's for this trial. I did read a paper the other day that compared immunomodulatory responses for MSC's derived from different tissue sources and as I recall both adipose and bone marrow derived cells worked well
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-504
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.81 |
Change
0.000(0.00%) |
Mkt cap ! $3.222B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1130 | $3.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.53 | 10 | 1 |
View Market Depth
| Last trade - 16.17pm 10/01/2025 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable
